Novo Nordisk insulin Ryzodeg passes Japan review
COPENHAGEN Nov 3 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, said on Monday its Ryzodeg insulin had passed the first review by an advisory committee to the health ministry in Japan.
Novo Nordisk said in a statement it expected to receive marketing authorisation for the treatment from the Ministry within a few months.
Price negotiations for another insulin, degludec, continued and were expected to be completed in the first quarter of 2013, the company said in the statement, adding the exact launch timing for Ryzodeg would be decided after a price listing for degludec.
(Reporting by Copenhagen Newsroom; Editing by Hans-Juergen Peters)
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |